FDA offers new draft guidance on cancer drug dose optimization with overhaul of maximum tolerated dose paradigm
Although sponsors of cancer drugs have historically gone after the maximum tolerated dose (MTD), particularly with chemotherapy, the FDA released new draft guidance today explaining how that traditional paradigm needs to be tweaked with more targeted cancer drugs.
The reforms are necessary as the FDA notes that this current paradigm can result in a recommended dosage that is poorly tolerated, adversely impacts quality of life, and may hurt a patient’s ability to remain on a drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.